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Abstract
Background: Although the World Health Organization recommends replacing quinine (QN) by artesunate due to
its increased efficacy and the higher tolerance to the drug in both adults and children, QN remains a first-line
treatment for severe malaria, especially in Africa. Investigations of microsatellite Pfnhe-1ms4760 polymorphisms in
culture-adapted isolates from around the world have revealed that an increase in the number of DNNND amino
acid motifs was associated with decreased QN susceptibility, whereas an increase in the number of
DDNHNDNHNND motifs was associated with increased QN susceptibility.
Methods: In this context, to further analyse associations between Pfnhe-1ms4760 polymorphisms and QN
susceptibility, 393 isolates freshly collected between October 2009 and January 2010 and July 2010 and February
2011, respectively, at the Hôpital Principal de Dakar, Senegal were assessed ex vivo for QN susceptibility, and their
genes were amplified and sequenced.
Results: Of the 393 Plasmodium falciparum clinical isolates collected, 145 were successfully cultured. The 145 QN
IC50s ranged from 2.1 to 1291 nM, and 17 isolates (11.7%) exceed the QN reduced susceptibility threshold of 611
nM. Among the 393 P. falciparum clinical isolates, 47 different alleles were observed. The three most prevalent
profiles were ms4760-1 (no = 72; 18.3%), ms4760-3 (no = 65; 16.5%) and ms4760-7 (no = 40; 10.2%). There were no
significant associations observed between QN IC50 values and i) the number of repeats of DNNND in block II
(p = 0.0955, Kruskal-Wallis test); ii) the number of repeats of DDNHNDNHNND in block V (p = 0.1455, Kruskal-Wallis test);
or iii) ms4760 profiles (p = 0.1809, Kruskal-Wallis test).
Conclusions: Pfnhe-1ms4760 was highly diverse in parasite isolates from Dakar (47 different profiles). Three profiles
(ms4760-1, ms4760-3 and ms4760-7) were predominant. The number of repeats for block II (DNNND) or block V
(DDNHNDNHNND) was not significantly associated with QN susceptibility. New studies, and especially in vivo
studies, are necessary to confirm the role of Pfnhe-1ms4760 as a marker of QN resistance.
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Background
Although the World Health Organization (WHO) recom-
mends replacing quinine (QN) with artesunate due to its
improved efficacy and the higher tolerance of the drug in
both adults and children [1,2], QN remains a first-line
treatment for severe malaria, especially in Africa, and is
still used as a second-line therapy in combination with
doxycycline, tetracycline or clindamycin for uncomplicated
malaria in many countries [3]. Despite the efficacy of QN
against chloroquine-resistant Plasmodium falciparum
isolates, reports of QN resistance (QNR) have been
increasing. In the 1980s, the frequency of clinical failures
increased in Southeast Asia [4-6], South America [7]
and Africa [8,9]. Despite the longevity of QN use, the
mechanisms of resistance (and its mode of action) have
not yet been resolved. QN, a quinoline derivative, is a
monoprotic weak base that accumulates within the
low pH environment of the parasite digestive vacuole
of P. falciparum. QN presumably acts by interference with
the detoxification of haem produced during haemoglobin
degradation by P. falciparum asexual blood stages [10].
The mechanism of QNR is complex and multigenic.
QNR has been associated with mutations in both the
P. falciparum multidrug resistance gene mdr1 (Pfmdr1)
[11] and the chloroquine resistance transporter gene Pfcrt
[12]. More recently, other genetic polymorphisms, such as
mutations in the resistance protein gene Pfmrp [13], have
been suggested to contribute to QNR. PfMRP knockout
parasites displayed an increased susceptibility to QN [14].
Using quantitative trait loci (QTL) on the genetic cross
of HB3 and Dd2 strains, Ferdig et al. identified genes
associated with reduced QN susceptibility on chromosome
5, encoding Pfmdr1, on chromosome 7, encoding Pfcrt,
and on chromosome 13, encoding the sodium/hydrogen
exchanger gene Pfnhe-1[15]. Sequences of Pfnhe-1
showed multiple and complex variations including point
polymorphisms at three separate codons (790, 894 and
950) and microsatellite variations in three different
repeat sequences (msR1, ms3580 and ms4760). However,
the three point polymorphisms and microsatellite polymor-
phisms msR1 and ms3580 showed no significant associa-
tions with QN susceptibility. Conflicting data have been
reported on Pfnhe-1 polymorphisms. However, the investi-
gations of the microsatellite ms4760 polymorphisms in
culture-adapted isolates from around the world showed
an association with the QN susceptibility phenotype [16].
A repetition of the amino acid motif DNNND was associ-
ated with a decreased susceptibility to QN based on the
clinical failure of QN in a traveller from Senegal [17], and
data from fresh isolates from Vietnam (n = 79) [18] and
from culture-adapted isolates from the China-Myanmar
border area (n = 60) [19], Asia, South America and Africa
(n = 95) [20]. In 29 cultured-adapted isolates from the
Kenya [21] and in 172 freshly obtained isolates from
Uganda [22], the duplication of the DNNND motif was
associated with a reduced susceptibility to QN compared
to isolates with one or more than two repeats. Moreover,
an increased number of DDNHNDNHNND motifs
were associated with an increased susceptibility to QN
[15,16,18-20]. Paradoxically, increased numbers of this
latter amino acid motif were associated with a reduced
susceptibility to QN based on 83 freshly obtained isolates
from Madagascar and 13 African countries [23]. Moreover,
these samples did not exhibit any associations between
the number of DNNND repeats and QN susceptibility.
Furthermore, there was no association between the number
of DNNND and DDNHNDNHNND repeats and QN
susceptibility based on freshly obtained isolates from the
Republic of Congo (n = 74) [24], Thailand (n = 85) [25],
Asia, South America and Africa(n = 90) [20].
In this context, to further analyse associations between
polymorphisms in Pfnhe-1ms4760 and QN susceptibility,
393 freshly obtained isolates from Dakar, Senegal were
assessed ex vivo for QN susceptibility and their genes were
amplified and sequenced.
Methods
Reference culture-adapted strains and clinical isolates of
Plasmodium falciparum
Between October 2009 and January 2010 and July 2010
and February 2011, 393 P. falciparum clinical isolates were
collected from patients with malaria recruited at the
Hôpital Principal de Dakar, a military hospital, in the
context of an evaluation of ex vivo malaria susceptibility to
anti-malarial drugs in Dakar [26,27]. Venous blood samples
were collected in Vacutainer® ACD tubes (Becton Dickinson,
Rutherford, NJ, USA) prior to patient treatment. Informed
verbal consent was obtained from patients and/or their par-
ents before blood collection. An assessment of P. falciparum
susceptibility to anti-malarial drugs was performed using
the same venous blood sample used for this diagnostic.
The study was reviewed and approved by the ethical
committee of the Hôpital Principal de Dakar.
Thin blood smears were stained using a RAL® kit
(Réactifs RAL, Paris, France) and were examined to
determine P. falciparum density and confirm monoinfection.
Parasitized erythrocytes were washed three times with
RPMI 1640 medium (Invitrogen, Paisley, UK) buffered
with 25 mM HEPES and 25 mM NaHCO3. If parasitaemia
exceeded 0.5%, infected erythrocytes were diluted to 0.5%
with uninfected erythrocytes (human blood type A+) and
re-suspended in RPMI 1640 medium supplemented with
10% human serum (Abcys S.A. Paris, France), for a final
haematocrit of 1.5%.
Drugs
QN was purchased from Sigma (Saint Louis, MO, USA)
and was dissolved first in methanol and then diluted in
Pascual et al. Malaria Journal 2013, 12:189 Page 2 of 8
http://www.malariajournal.com/content/12/1/189
water to final concentrations ranging from 5 nM to 3200
nM. Batches of plates were tested and validated using
the CQ-susceptible 3D7 strain (West-Africa) and the
CQ-resistant W2 strain (Indochina) (MR4, Virginia,
USA) in three to six independent experiments using the
conditions described in the paragraph below. The two
strains were synchronized twice with sorbitol before use
[28], and clonality was verified every 15 days using PCR
genotyping of the polymorphic genetic markers msp1 and
msp2 and using microsatellite loci [29,30] and additionally
verified each year by an independent laboratory from the
Worldwide Anti-malarial Resistance Network (WWARN).
Ex vivo assay
For in vitro isotopic microtests, 200 μl of synchronous
parasitized red blood cells (final parasitaemia, 0.5%; final
haematocrit, 1.5%) was aliquoted into 96-well plates
pre-dosed with anti-malarial drugs. The plates were
incubated in a sealed bag for 42 h at 37°C with the
atmospheric generators for capnophilic bacteria Genbag
CO2® at 5% CO2 and 15% O2 (BioMérieux; Marcy lEtoile,
France) [31]. After thawing the plates, haemolysed cultures
were homogenized by vortexing the plates. Both the
success of the drug susceptibility assay and the appropriate
volume of haemolysed culture to use for each assay were
determined for each clinical isolate during a preliminary
pLDH ELISA. Both pre-test and subsequent experimental
ELISAs were performed using a commercial kit (ELISA-
Malaria antigen test, ref 750101, DiaMed AG, Cressier
s/Morat, Switzerland) as previously described [32]. The
optical density (OD) of each sample was measured with
a spectrophotometer (Multiskan EX, Thermo Scientific,
Vantaa, Finland).
The concentration at which the drugs were able to
inhibit 50% of parasite growth (IC50) was calculated with
the inhibitory sigmoid Emax model with an estimation
of the IC50 through non-linear regression using a standard
function of the R software (ICEstimator version 1.2) [33].
IC50 values were validated only if the OD ratio (OD at
concentration 0 / OD at concentration max) was superior
to 1.8 and the confidence interval ratio (upper 95%
confidence interval of the IC50 estimation/lower 95%
confidence interval of the IC50 estimation) was inferior
to 2.0 [33].
Genotyping of the Pfnhe ms4760 microsatellite
polymorphisms
Parasite DNA from 100 μl of infected blood was extracted
using the E.Z.N.A. Blood DNA kit (Omega Bio-Tek,
GA, USA). A sequence containing the previously described
ms4760 microsatellite [15] was amplified using pfnhe-
3802 F 5-TTATTAAATGAATATAAAGA-3 and pfnhe-
4322R 5-TTTTTTATCATTACTAAAGA-3 primers.
Sequencing was performed using ABI Prism Big Dye
Terminator v1.1 Cycle Sequencing Ready Reaction Kits
(Applied Biosystems, CA, USA), according to the
manufacturers instructions. Sequences were analysed
with BioEdit sequence alignment editor (version 7.0.9.0)
software.
Statistical analysis
Data were analysed using R software (version 2.10.1).
Differences between the QN IC50 values of isolates
harbouring DNNND repeats, DDNHNDNHNND repeats
or profiles were compared using the Kruskal-Wallis test.
Results
Of the 393 P. falciparum clinical isolates collected at the
Hôpital Principal de Dakar, 145 isolates were successfully
cultured. The 145 QN IC50s ranged from 2.1 to 1291 nM,
and 17 isolates (11.7%) exceeded the QN-reduced-suscep-
tibility threshold of 611 nM that has been previously
defined [31].
Among the 393 P. falciparum clinical isolates, 47
different alleles were observed, including five profiles not
previously described (from ms4760-109 to ms4760-113)
(Figure 1). The amino acid sequence alignments of these
47 profiles are described in Figure 2. The three most
prevalent profiles were ms4760-1 (no = 72; 18.3%),
ms4760-3 (no = 65; 16.5%) and ms4760-7 (no = 40; 10.2%).
The number of repeats for block II (DNNND) ranged
from zero to four, and the number of repeats for block V
(DDNHNDNHNND) ranged from one to three (Figure 3).
For block II, groups with one repeat (33.1%), two repeats
(33.8%) and three repeats (29.5%) represented the majority
of the 393 isolates. For block V, the group with two
repeats alone represented 63.4% of the isolates.
There was no observed significant association between
QN IC50 values and the number of repeats of DNNND
in block II (p = 0.0955, Kruskal-Wallis test) (Table 1).
The 145 isolates were classified into two groups: < 2
repeats of DNNND and ≥ 2 repeats. The QN IC50 values
were not significantly different in the group < 2 repeats
of DNNND in block II (mean IC50 = 184.1 nM, 95% confi-
dence interval 134.6-252.4) compared with the group ≥ 2
repeats of DNNND in block II (mean IC50 = 153.5 nM,
95% confidence interval 123.3-191.0) (p = 0.2224, Kruskal-
Wallis test).
There was no observed significant association between
QN IC50 values and the number of repeats of DDNHN
DNHNND in block V (p = 0.1455, Kruskal-Wallis test)
(Table 2). The 145 isolates were classified into two
groups: < 2 repeats of DDNHNDNHNND and ≥ 2
repeats. The QN IC50 values were not significantly
different in the group < 2 repeats of DDNHNDNHNND in
block V (mean IC50= 134.0 nM, 95% confidence interval
95.9-187.1) in comparison to the group ≥ 2 repeats of
DDNHNDNHNND in block V (mean IC50 = 175.8 nM,
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95% confidence interval 142.2-217.3) (p = 0.1084, Kruskal-
Wallis test).
Additionally, there was no observed significant asso-
ciation between QN IC50 values and ms4760 profiles
(p = 0.1809, Kruskal-Wallis test) (Table 3).
Discussion
QN has been used to treat malaria for more than
350 years in Africa, with little emergence and spread of
resistance. Although WHO recommends replacing QN
with artesunate, QN remains the first-line anti-malarial
treatment for complicated malaria in Europe and Africa.
Although QN has retained good anti-malarial efficacy in
most areas, its clinical efficacy has decreased in some
regions. The first cases of QN clinical failure were
observed in Brazil and Asia in the 1960s; then in the
1980s, clinical failures became more frequent in Southeast
Asia, South America and Africa [4-9]. However, QN
resistance is not yet a significant problem in Africa, and
QN remains both the first-line drug used to treat severe
malaria and a second-line therapy for uncomplicated
malaria in some areas of Africa.
Even in areas where QN remains effective, such
as sub-Saharan Africa, the susceptibility of individual
P. falciparum isolates to QN has varied widely. The
IC50s for isolates collected in Senegal were 31 to 765
Figure 1 The distribution of Pfnhe-1ms4760 profiles among the 393 P. falciparum isolates from Dakar, Senegal collected from October
2009 until February 2011.
Figure 2 The amino acid alignment of the 47 Pfnhe-1ms4760 haplotypes found in the 393 P. falciparum isolates from Dakar, Senegal
collected from October 2009 until February 2011.
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nM in 1984 (Thies and Kaolack) [34], 5 to 932 nM in
1996 (Dielmo) [35] and 6 to 1291 nM in 2009 (Dakar)
[26]. Many other studies have reported wide ranges of
susceptibility to QN: 25 to 1253 nM in Comoros [36],
36 to 1097 nM in the Republic of Congo [24] (studies
assessed in the same conditions as studies in Senegal in
1996 and 2009) or 15 to 761 nM in Uganda [22]. The
wide range of QN susceptibility and recent evidence for
QN treatment failure seen across Africa [8,9,17] suggest
that the evolution of parasites with reduced susceptibility
may contribute to decreased QN efficacy.
Although some reports of QN treatment failure exist,
it is difficult to confirm QN resistance because of the
drugs short elimination half-life, the requirement to
administer it three times a day for at least five days, drug
intolerance that often leads to poor compliance and a
lack of reliable data on the correlation between QN IC50
and clinical failure.
Even if WHO recommends replacing QN with artesunate
as first-line anti-malarial treatment for complicated malaria,
maximizing the efficacy and longevity of QN remains
important and will depend critically on the pursuit of
intensive research towards the identification of in vitro
markers of QNR and the implementation of ex vivo and
in vivo surveillance programs, such as those championed
by the WorldWide Antimalarial Resistance Network
[37,38]. Specifically, there is a need to identify molecular
markers that effectively predict QN resistance and enable
the active surveillance of temporal trends in parasite
susceptibility [39]. The present study aimed to evaluate
the association between the Pfnhe polymorphism and QN
susceptibility in freshly obtained isolates from Dakar,
Senegal to assess the validity of Pfnhe as a molecular
marker of QN susceptibility in this region.
Prior to this report, no data were yet available on the
sequence variation of Pfnhe-1ms4760 in P. falciparum
parasites from Senegal. Among the 393 studied sequences,
47 different alleles were observed in samples from Dakar.
Consistent with previous reports [22,24,40], Pfnhe-1ms4760
was highly diverse among parasite isolates. It appears that
polymorphisms are more important in Africa and the
Indian Ocean region than in India or Asia: in Senegal, 47
different profiles (393 samples) were observed; in the
Republic of Congo, 27 different profiles (74 samples) [24];
in Uganda, 40 different profiles (172 samples) [22]; and in
the Indian Ocean, 29 different profiles (595 samples) [40],
whereas in Vietnam, only ten different profiles (79
samples) were observed [18]; in the China-Myanmar
border area, ten different profiles (60 samples) [19]; and
Figure 3 The distribution of Pfnhe-1 profiles according to the number of repeats in block II (DNNND) and block V (DDNHNDNHNND).
Table 1 The distribution of QN IC50 according to the










1 51 187.1 136.1-257.6
2 48 189.7 141.6-254.1
3 41 126.8 89.1-179.9
4 4 88.1 24.5-316.9
Table 2 The distribution of QN IC50 according to the










1 37 129.4 92.7-181.1
2 94 168.7 133.7-213.3
3 14 228.6 138.7-376.7
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in India, 16 different profiles (244 samples) [41]. This
situation likely reflects the level of transmission in these
areas and the level of QN selection pressure. The genetic
diversity of ms4760, assessed by Neis unbiased expected
heterozygosity (He), was significantly higher in African
isolates (ranged from 0.66 to 0.85) and Indian isolates
(0.68) than in Asian isolates (0.49 to 0.68) [40]. Only three
profiles (ms4760-1, ms4760-3 and ms4760-7) of the four
expected predominant profiles (ms4760-1, ms4760-3,
ms4760-6 and ms4760-7) [18-24,40,41] were found to
predominate in Senegal. Profile ms4760-6 represents only
1.8% of the studied sequences. The predominance of these
three profiles combined with a low rate of the ms4760-6
profile was also found in parasites collected before QN
treatment and in recurrent parasites in Mali [42].
The 145 QN IC50s ranged from 2.1 to 1291 nM and, in
17 isolates (11.7%), exceeded the QN-reduced-susceptibil-
ity threshold of 611 nM that has been previously defined
[31]. In this study, the number of repeats for block II
(DNNND) or block V (DDNHNDNHNND) was not
significantly associated with QN susceptibility. These data
are similar to those found in freshly obtained isolates from
Asia, South America and Africa [20], the Republic of
Congo [24] or Thailand [25]. The reduced susceptibility to
QN was associated with an increased number of DNNND
repeats or with two repeats, and the increased susceptibility
to QN associated with an increased number of DDNHN
DNHNND repeats was found more often in culture-
adapted parasites [19-21]. Given that the influence of
Pfnhe on QN susceptibility has been shown to be parasite-
dependent, these apparently conflicting results may be
explained, in part, by differences in the geographic origin
of the parasites analysed, as their local selection history
and genetic background varies, and by the method used to
assess in vitro susceptibility to QN (i.e. an in vitro test for
culture-adapted isolates or strains versus an ex vivo test
for freshly obtained isolates) [20].
One explanation for these differences could be variation
in genetic background. A specific genetic background
observed in Asia may allow the observed contribution of
Pfnhe polymorphism to QN in vitro susceptibility. This
explanation is consistent with the following: i) the first
evidence of Pfnhe-QN resistance association from QTL
analysis using Americano-Asian cross strains [15], ii) that
most associations identified have been shown among
Asian strains [15,16,18,19] and iii) that at least five genes
spanning the P. falciparum genome influence the QNR
in vitro phenotype with an additive effect or with pairwise
interactions [15].
Additionally, these genetic dissimilarities between African
and Asian Plasmodium populations may be accentuated
by different local selection histories. The best-documented
genomic modifications by a local selection process relate
to drug pressure. Several studies have shown that drug
pressure may involve extended linkage disequilibrium
around a drug resistance associated gene [43]. This is
characterized by a strong loss of genetic diversity called a
selective sweep. This process stretch may be modified by
either i) drug use or ii) malaria transmission level. A
reduced drug use and higher malaria transmission level in
Africa would be consistent with the lower selective sweep
and an absence of linkage disequilibrium between Pfnhe
and other cooperative drug response genes or selected
compensatory mutations. For example, the QTL analysis
of chromosome 13 located 60 genes of unknown function
as being close to Pfnhe [15]. They would be more or less
linked depending on drug pressure and malaria transmis-
sion levels if QN pressure selects at least one of them. In
Kenya, there is an association between two DNNND
repeats in the ms4760 Pfnhe microsatellite and a reduced
susceptibility to QN in 29 P. falciparum isolates [44]. This
is consistent with the historic precedent of the spread of
drug resistance around the world. The emergence of
chloroquine resistance in Asia was followed by an initial
introduction into East Africa and subsequent spread
across the African continent. Geographic proximity may
explain plasmodial population migration. Moreover, East
African plasmodial populations may exhibit genetic
dissimilarities to other African populations [29].
As the QN response is controlled by multiple genes
with complex interactions, one would expect: i) a higher
sensitivity to genetic background than if the response
were controlled by only one gene, ii) higher sensitivity
to parameters that might cause linkage disequilibrium
between genes and iii) various combinations of gene
polymorphisms that might result in similar QN resistance
phenotypes.
The three profiles (ms4760-1, ms4760-3 and ms4760-7)
were predominant in parasites collected before QN treat-
ment and in recurrent parasites in Mali [42]. The preva-
lence of ms4160-1 increased significantly from 26.2% to
46.3% after QN treatment in recurrent parasites. QN
treatment selected for the Pfnhe-1ms4760-1 profile. The
profiles ms4760-3 and ms4760-18 were found in recurrent
parasites from a patient returning from French Guiana
and Senegal who failed with QN treatment [17,45]. Such
in vivo studies are necessary to confirm the role of
Table 3 The distribution of QN IC50 according to the







Ms4760-1 25 234.4 166.3-330.4
Ms4760-3 27 181.6 109.1-302.0
Ms4760-7 14 123.0 77.5-195.9
Ms4760-18 11 212.3 122.2-369.0
Ms4760-other 68 140.3 106.4-185.4
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Pfnhe-1ms4760 as a marker of QN resistance. However,
according to both previous studies and this current one,
as Pfnhe-1 exhibits inconsistent association with QN
susceptibility, the current problem should be to identify
the new other marker that will be best associated with
reduced QN susceptibility.
Conclusion
Pfnhe-1ms4760 was highly diverse in parasite isolates
in Dakar (47 different profiles). Genetic diversity
should be assessed. Three profiles (ms4760-1, ms4760-3
and ms4760-7) were predominant. The number of repeats
for block II (DNNND) and block V (DDNHNDNHNND)
was not significantly associated with QN susceptibility.
New studies, and especially in vivo studies, are necessary
to confirm the role of Pfnhe-1ms4760 as a marker of QN
resistance. Studies should aim to identify partners of
Pfnhe-1 or other polymorphisms linked to Pfnhe-1.
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